*** RETAINED DUPLICATE: THIS CASE WAS ALSO PREVIOUSLY REPORTED AS GENENTECH CASE = 
INITIAL INFORMATION FOR THIS NON-ROCHE STUDY CASE (NO STUDY NUMBER) WAS RECEIVED ON 17 
DEC 2010 FROM A PHYSICIAN AND CONCERNS AN APPROX. 70-YEAR-OLD MALE PATIENT WHO 
EXPERIENCED PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WHILE TREATED WITH 
RITUXIMAB FOR LYMPHOMA. NO PATIENT NUMBER WAS PROVIDED.
NO MEDICAL HISTORY, CONCURRENT CONDITIONS AND PAST DRUGS WERE REPORTED. 
CONCOMITANT MEDICATION INCLUDED NOT FURTHER SPECIFIED CHEMOTHERAPY.
THE PATIENT COMMENCED RITUXIMAB ON AN UNREPORTED DATE. LAST APPLICATION WAS ON 20 OCT
2010 (EST.). ON AN UNREPORTED DATE THE PATIENT EXPERIENCED PROGRESSIVE MULTIFOCAL 
LEUKOENCEPHALOPATHY. JC VIRUS WAS CONFIRMED. THERAPY WITH RITUXIMAB WAS 
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 300 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
DISCONTINUED. THE EVENT WAS PERSISTING.
THE PHYSICIAN ASSESSED THE EVENT AS RELATED TO RITUXIMAB BUT DID NOT PROVIDE ANY 
SERIOUSNESS CRITERION. THE COMPANY ASSESSED THE EVENT AS MEDICALLY SIGNIFICANT.
Additional information was received on 25 October 2011:
On an unspecifed date, the patient experienced Progressive multifocal leukoencephalitis (previously reported as 
Progressive multifocal leukoencephalopathy).  On an unspecified date, the patient died.
The reporter did not assess the causal relationship between fatal Progressive multifocal leukoencephalitis and 
Rituximab.
No further information was provided.
Following review on 22/May/2014, the following information originally received on 17/Dec/2010 was corrected: The 
protocol number was amended from unknown to an interventional clinical study (details unknown).